Small molecule Evrysdi overtakes new modalities to dominate SMA market

Revenue from Evrysdi, an oral small molecule, has taken over new modality spinal muscular atrophy therapies. Evrysdi sales surpassed those of antisense Spinraza and gene therapy Zolgensma, indicating that traditional modalities still hold their own, even in the face of potential one-time or less frequent treatments.

The three drugs collectively brought in $1.3 billion in 2Q24, a new high for the SMA market, topping 3Q23 when they totaled $1.15 billion. ...